However, the clinical values of SLC25A25-AS1 and the risk model warrant further validation in clinical samples and analysis of the roles and signaling mechanisms of SLC25A25-AS1 in PC cell growth, migration, and tumorigenicity should be conducted in xenograft models. This evidence concerns the gene SLC25A25 and pachyonychia congenita.